Dr. Victor Velculescu, CEO and founder of Delfi Diagnostics. Baltimore life sciences company Delfi Diagnostics is $225 million closer to bringing its blood test for early detection of cancer to the ...

DELFI Diagnostics has clinically validated FirstLook Lung, its blood test designed to improve early detection of lung cancer, which remains the leading cause of cancer deaths in the United States. At ...

Provider of Accessible Blood-Based Tests for Cancer Detection Highlights Results of Clinical Trial in Preeminent Peer-Reviewed Publication The company currently has an active pipeline of biotech and ...

Delfi Diagnostics has put forward a new cancer monitoring test that searches the blood for broken pieces of tumor DNA, and it is kicking off the test’s launch with a collaboration with Immunocore to ...

PALO ALTO, Calif. and BALTIMORE, Feb. 1, 2024 /PRNewswire/ -- DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced ...

PALO ALTO, Calif., Jan. 8, 2026 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of accessible blood-based, liquid biopsy tests that deliver a new way to enhance early cancer detection, today ...

BALTIMORE and PALO ALTO, Calif., May 12, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection ...

CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the ...

DELFI leadership to announce advancement with whole-genome machine learning for lung cancer detection test at HLTH 2023; Presentation of DELFI's L101 clinical validation study at CHEST Annual Meeting ...

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who ...